Back to Results
First PageMeta Content
Adjuvant therapy / Breast cancer / Chemotherapy / Docetaxel / Neoadjuvant therapy / Medicine / Cancer treatments / Bevacizumab


Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of the HER2-negative cohort of the GeparQuinto study (GBG 44) Bernd Gerber1, Sibylle Loibl 2, Michael Untch3, Holger Eidtmann4, Mahdi
Add to Reading List

Document Date: 2014-12-11 08:08:18

Open Document

File Size: 2,26 MB

Share Result on Facebook

City

Düsseldorf / München / Ulm / Kiel / Klinikum Offenbach / Berlin / Rheinfelden / Hannover / Erlangen / Frankfurt/Main / Frankfurt / San Antonio / Magdeburg / Tübingen / Rostock / Neu-Isenburg / /

Company

7Chop GmbH / /

Country

Germany / /

Currency

pence / /

/

Facility

Johannes Hospital / /

IndustryTerm

study groups / /

MedicalCondition

HER2-negative tumors / cancer / primary invasive non-breast cancer / breast cancer / hormone receptor-positive tumors / tumours / /

MedicalTreatment

neoadjuvant therapy / neoadjuvant treatment / chemotherapy / surgery / /

Organization

European Central Bank / Johannes Hospital Dortmund / /

Person

Bernd Gerber / Mahdi Rezai / Sibylle Loibl / Bev Yes / Ann Oncol / /

/

Product

paclitaxel / cyclophosphamide / /

Technology

chemotherapy / /

SocialTag